Stay updated on Vatiquinone for Mitochondrial Disease and Refractory Epilepsy Clinical Trial

Sign up to get notified when there's something new on the Vatiquinone for Mitochondrial Disease and Refractory Epilepsy Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Vatiquinone for Mitochondrial Disease and Refractory Epilepsy Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-13T20:19:31.000Z thumbnail image
  4. Check
    4 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the study details related to the efficacy and safety evaluation of Vatiquinone for treating mitochondrial disease in participants with refractory epilepsy.
    Difference
    0.1%
    Check dated 2024-06-06T14:17:40.000Z thumbnail image
  7. Check
    25 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to include detailed eligibility criteria for participants, such as signed informed consent, ability to complete seizure diaries, and genetic confirmation of mitochondrial disease with associated epilepsy phenotype.
    Difference
    31%
    Check dated 2024-05-22T20:32:56.000Z thumbnail image
  8. Check
    46 days ago
    Change Detected
    Difference
    1%
    Check dated 2024-04-30T22:17:43.000Z thumbnail image

Stay in the know with updates to Vatiquinone for Mitochondrial Disease and Refractory Epilepsy Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Vatiquinone for Mitochondrial Disease and Refractory Epilepsy Clinical Trial page.